Note: Descriptions are shown in the official language in which they were submitted.
CA 02196416 1997-01-30
RECOMB INANT HERPES VIRUS WITH., GENE PROMOTER
The present invent.i.on relates to a novel
recombinant virus; which can r xp7 - an exocenous gene in
an animal cell or in an. animal. body and can persistently
infect even in 1. he prese:: roc e of a materna:i ant i.body to
continue antigen st:iinu i.at . >n tar l_ Ong period of t Lme
while escaping from c:hallenge~ of tide ghost immune system,
thereby providing a vaccine which is effective even for
animals having a maternal antibodyõ The present invention
also relates to a polyvalent live vaccine for animals
using said recombinant:: The present invention
further relates 1:o a X-e<:.ombinant vi,:-us vector which can be
used as a drug delivery syanem ((C:)[7S) for production of
physiologically active str.> ys:7t:.anr_e:;s such as hormones or
cytokines within the living body.
Virus vectors have been studied widely for
vaccination efficiency and for use as a gene introduction
system into the living body. Particularly in the poultry
industry, studies of the application of poxvi:ruses,
especially fow:Lpox virus, have made t apid. progress. Under
the circumstances, in order to develop a more efficient
vector, the present inventors have investigated to make a
vector from Marek, s disease virus type 1 (hereinafter also
referred to as "MDV1"), a kind of avian herpes viruses,
and have reported many results thereof. For example,
the present inventors have investigated more than 20
4
CA 02196416 1997-01-30
- 2 -
sites on the MDV1 genome, and as a result, have identified
US10 gene as an T.nsertion site for an exogenous gene which can
stably retain an exogenous gene but does not impair the
vaccine effects against. M.az:ek' disease [Japanese patent
application tiro. 4-205933 (,:aE?ane.~ c patent publication No. 6-
22757) ; 4th International Symposium on Marek's Disease (1992),
Amsterdam; Vaccine 1994 Vol. 12, 953-957). A recombinant
virus which incorporates F protein gene of Newcastle disease
virus into the US10 gene exhibited sufficient effects as a
vaccine in SPF chickens, said effects being persistent over
at least 24 weeks after inoculation (4th International
Symposium on Marek's Disease (1992), Amsterdam). This
recombinant virus has been proved to show protective effects
against both Marek's disease and Newcastle disease even in
chickens having maternal antibodies but the protective effects
were somewhat lowered than in SPF chickens. That is, this
recombinant virus showed efficiently 100% protective effects
against Newcastle disease in SPF chickens whereas it showed
somewhat lowered effects, i..e. 70 to 90% level, in field
chickens having maternal antibodies (Current Developments in
the Molecular Biology of Marek's Disease Virus Workshop, 1995,
Florida). Such a decrease in the effects was supposedly due
to suppression of in vivro growth of the recombinant virus by
maternal antibodies against Newcastle disease and Marek's
disease when field chickens are immunized with the recombinant
virus.
44
CA 02196416 1997-01-30
- 3 -
As mentioned abOVE;: , when a live vaccine comprising
a recombinant virus is inocular,.ed into an animal having
maternal antibodies, a problem arises that said virus is
eliminated or viral growth is inhibited by the host immune
system such as maternal antibodies. Thus, an improved
recombinant virus is desired which retains the properties of
a live vaccine and can continuously provide antigen stimula-
tion for a long period of time while escaping from the
challenge of the immune system.
In order to solve the above-mentioned problem, the
present inventors have noted promoters derived from MDV1 and
have cloned several putative promoter genes from Marek's
disease virus (hereinafter also referred to as "MDV") genome.
Using these promoter genes, the present inventors have
conducted an experiment for expression of an exogenous gene
in a recombinant virus comprising said genes. As a result,
it was found, that among several promoter genes which the
present inventors have cloned, a promoter from glycoprotein
B (hereinafter referred to as "gB'") gene, a gene homologous
to herpes simplex virus gB gene, exhibited particularly
excellent effects in expression of an exogenous gene (e.g.
Newcastle disease virus F protein (hereinafter also referred
to as "NDV-F")), and in addition, exerted much improved
immunization effects in animals than expected. That is, an
amount of F protein expressed with this promoter in culture
cells was apparently lower than that of a recombinant virus
with conventional promoters (e.g. SV40 promoter), but
CA 02196416 2010-03-22
4 -
nevertheless quite a high immunogenicity in animals (chickens)
was observed contrary to expectations, i.e. a recombinant
virus with this promoter exhibited more protective effects
against Newcastle disease than those of the conventional
recombinant viruses and steadily exhibited the protective
effects of more than 95% even when it is used for immunization
of field chickens having a maternal antibody, effective
immunization of animals with a maternal antibody having been
a pending problem.
In one particular embodiment the invention provides
a recombinant herpes virus which incorporates an exogenous
gene expression cassette in which a herpes virus-derived gB
gene promoter is used as a promoter for expression of an
exogenous gene, wherein said gB gene promoter is the same as
one contained in the recombinant herpes virus and wherein said
gB gene promoter is of about 500 nucleotides in length and
comprises a sequence of from about nucleotide 61 to nucleotide
557 in SEQ ID NO:1.
In the drawings:
Fig. 1 is a schematic illustration of cloned
putative gB promoter fragments.
Fig. 2 shows a nucleotide sequence upstream of gB
gene as well as each position of primers used for nucleotide
sequence determination and PCR primers.
CA 02196416 2010-03-22
4a -
Fig. 3 shows construction of insertion vector
plasmids (pKA4BPF and pKA4BNF) for expression of NDV-F protein
with gB promoter.
Fig. 4 shows a theoretical scheme of insertion of
gB promoters and NDV-F gene for US10BPF and USIOBNF as well
as a position of fragment A4 used for construction of the
insertion vector plasmid.
Fig. 5 shows results of Southern hybridization of
digestion products with restriction enzyme PstI of DNA
extracted from CEFs infected with the recombinant virus
US10BPF or US1OBNF, using fragment P from gB promoter or
fragment A4 as a probe.
CA 02196416 1997-01-30
Fig. 6 is a graph showing a change of an anti-F
antibody titer In ELISA for chickens inoculated with the
recombinant virus USIOBPF, 1JS1OBNF or US10BLF and chickens
without inoculation.
Fig. 7 is a graph showing a change of an anti-F
antibody titer in ELISA for chickens inoculated with the
recombinant virus US10BPF.
In view of excellent protective effects obtained in
the immunization experiment as mentioned above, herpes virus-
derived gB promoter used in the present invention supposedly
have the characteristics as mentioned hereinbelow.
That is, Marek's disease live vaccine viruses
persistently infect the body of chickens in spite of the
presence of neutralizing antibodies in blood thereby to induce
a high antibody titer against MDVs. Although a mechanism is
unknown where the virus circumvents the host immune system to
continue to induce an antigen stimulation, one possibility
might be that a tissue where latent infection of the virus is
present is distinct from a tissue where an antigen (e.g. gB)
is expressed. That is, it is estimated that, in a tissue
where latent infection of Marek's disease virus is present,
a target antigen for the immune system is not expressed, and
as a result, the virus can escape from the guard of the host
immune system. Such a latent virus is supposedly often
activated and stimulates the immune system possibly by
infecting another tissue where it expresses a viral
A
CA 02196416 1997-01-30
antigen, thereby a high product Lon of an antibody being
induced.
gB, expression of which is intrinsically
controlled by gF3 gene promoter, the promoter successfully
cloned in the present invention, is a glycoprotein which
induces neutralizing antibody production against the virus.
It is estimated that although production of an antibody
against the gB (i.e. a neutralizing antibody) is induced in
MDV-infected chickens, MDVs escape from the neutralizing
antibody and infect persistently to cause an antigen stimula-
tion to thereby induce a high antibody titer. That is, it was
estimated that g13 promoter expresses gB in specific cells but
not in those cells where MDVs are latent, and as a result,
MDVs can persistently infect while escaping from the host
immune system. Accordingly, by .ising the gB promoter for
expression of Newcastle disease virus F protein, the expres-
sion of F protein is similarly controlled by the gB promoter,
and as a result, a recombinant virus acquired properties of
persistent infection while escaping from the challenge of the
host immune system.
On the contrary, for SV4O-derived promoter incorpo-
rated into various recombinant viruses, which the present
inventors have hitherto constructed, although a. promoter
activity itself is well potent, the recombinant viruses
express F protein even on the surface of those cells where
latent infection might be possible, and as a result, the
viruses are targeted by the immune host system and hence
A
CA 02196416 1997-01-30
easily eliminated frcm within the living body, due to the
absence of the control mechanism as mentioned above. Under
the circumstances, especially in the presence of maternal
antibodies, it was estimated that the recombinant viruses
could not sufficiently propagate due to more rapid elimination
by the immune system.
Other glycoproteins homologous to MDV-gB are well
preserved in a number of herpes viruses and are considered to
be an antigen responsible for protection from infection (R.
Eberl et al., J. Med. Viral. 27: 309-316 (1989)). In view of
this, for not only Marek's disease virus but also another
herpes viruses used as a vector, the use of gB gene promoter
was considered to be quite effective for efficient expression
of an exogenous gene of interest and maintenance of the
vaccine effect for a long period of time. In a preferred
embodiment, an effective recombinant herpes virus is prepared
using a gB promoter gene from herpes virus (i.e. a gB
promoter gene which is intri.nsicaity contained in said herpes
virus). Such herpes viruses include, in addition to MDV,
herpes virus saimiri [R.C. Desrosiers et al. Molecular and
Cellular Biology 5, 2796-2803 (1994)]; Aujeszky's disease
virus [K.L. Glazenburg et al., J. Virology, 69, 189-197
(1995)]; herpes simplex virus type 1. (hereinafter referred to
as "HSV1") [H.J. Federoff et at., Proc. Natl. Acad. Sci. USA
59, 1636-1640 (1992)]; herpes simplex virus type 2 (hereinaf-
ter referred to as "HSV2") [J.B. David et al., Virology 155,
322-333 (1986)]; herpes zoster virus [R.S. Lowa et al., Proc.
A
2196416
8 -
Natl. Acad. Sci. USA 84, 3896-3900 (1987)]; equine herpes
virus type 1 [A.R. Elizabeth et al., Virology 189, 304-316
(1992)]; bovine herpes virus type 1 (hereinafter referred to
as "BHV1") [J.C. Whitbeck et al., J. Virology 62, 3319-3327
(1988)]; bovine herpes virus type 2 (hereinafter referred to
as "BHV2") [W. Hammerschmitdt et al., Virology 165, 388-405
(1988)]; feline herpes virus type 1 [R. S . Spaete et al., Proc.
Natl. Acad. Sci. USA 84, 7213-7217 (1987); Naoaki Yokoyama et
al., 119th Japan Veterinary Society, Brief Text, p116 (1995)];
turkey herpes virus (hereinafter referred to as "HVT") [P.J.
Sondermeijer et al., Vaccine, 11, 349-358 (1993)]; human
cytomegalovirus (hereinafter referred to as "HCMV") [J.K.
McDougall, Cytomegaloviruses, Springer-Verlag, Berlin-
Heidelberg]; human herpes virus type 6 (hereinafter referred
to as "HHV6") [K. Ellinger et al., J. Gen. Virol. 74, 495-500
(1993)]; human herpes virus type 7 (hereinafter referred to
as "HHV7") [Atsuko Haneda et al., 42th Japan Virology Society,
Brief Text, p166 (1994)]; Epstein-Barr virus (hereinafter
referred to as "EBV") [A.J. Davison et al., J. Gen. Virol. 68,
1067-1079 (1987)], and the like.
According to the present invention, in addition to
the above-mentioned effects that an exogenous gene expression
is controlled in host cells inoculated with the virus, there
can also be obtained effects that the promoter gene fragments
for expression of an exogenous gene are shorter than the
conventional promoters such as SV40 promoter and thus, by the
shortened portion, a longer structural gene (exogenous gene)
2196416
9 -
for expression can suitably be incorporated into a plasmid so
that construction of plasmid and a recombinant virus becomes
easier.
The present invention is explained in more detail
by referring to, by way of example, a recombinant virus in
which MDV is employed as herpes virus.
The present inventors have cloned 5' site of the
genes encoding gB, US10, US537 and US420 [Sakaguchi et al.,
Virus Gene 6, p365-378 (1992)] as a MDV-derived promoter and,
using these gene fragments, have conducted an experiment for
expression of an exogenous gene. As a result, the 5' fragment
of gB gene among these promoters could successfully express
the exogenous gene in culture cells and thus gB promoter was
selected for further investigation as described below.
The gB gene's position on the MDV1 genome has been
reported by Anne E. Buckmaster et al. [J. Gen. Virol. 69,
p2033-2042 (1988)]. Thereafter, nucleotide sequences of gB
gene and upstream thereof up to -360 bases have also been
reported [L.J.N. Ross et al., J. Gen. Virol. 70, p1789-1804
(1989)]. However, there has yet been no report on the
identification of a promoter region involved in expression of
gB gene as well as activities thereof. Thus, the present
inventors have firstly identified the promoter region for use
in a recombinant virus.
First, referring to the nucleotide sequence reported
by Ross et al. [J. Gen. Virol. 70, p1789-1804 (1989) ], primers
CA 02196416 1997-01-30
- 10 --
were designed and a further upstream nucleotide sequence was
determined by the primer extension method.
Then, a 51 primer was designed within the determined
region and a 31 primer just before the gB open reading frame
(ORF), and about 500 nucleotides were amplified by PCR and
cloned. Then, to the downstream of said nucleotides was
ligated an F protein gene of NDV to construct an expression
plasmid. Similarly, using only the 3' half of the nucleotides
amplified by PCR, a plasmid for expression of the F protein
gene was constructed and subjected to experiment.
For measuring promoter activities, the expression
in culture cells was first confirmed. That is, the plasmids
were introduced into chicken embryo fibroblasts (CEF) and the
expression of F protein was detected by the fluorescent
antibody method using a monoclonal antibody recognizing F
protein. Then, recombinant viruses were constructed using
each plasmid and F protein expression in each recombinant
virus was confirmed. As a final experiment, each of the
recombinant viruses was inoculated into chickens having
maternal antibodies and immunogenicity thereof was compared.
As a result, there was no difference between the recombinant
viruses in an expressed amount of F protein in culture cells
whereas immunogenicity after inoculation into chickens
unexpectedly differed significantly. That is, it was found that
the recombinant virus with the whole nucleotide sequence amplified
by PCR showed extremely high immunogenicity while the
= S - 2196416
- 11 -
recombinant virus comprising only the 3' half of the amplified
sequence as a promoter exhibited extremely low immunogenicity.
Thus, as a gB promoter region for expression of an
exogenous gene in a recombinant virus, not only up to about
200 to 300 nucleotides upstream of the translation initiation
codon, commonly a minimum region as a promoter, but also
further upstream region of from -262 nucleotide up to -561
nucleotide (cf. Fig. 2) containing a transcriptional control
factor are critical. That is, it was shown that the minimum
requisite sequence for promoter is contained within about the
3' half of the cloned sequence of around 500 nucleotides in
view of the F protein expression in culture cells, but the
transcriptional control region contained in the 5' half of the
cloned sequence plays an important role in efficient expres-
sion within the living body of chickens.
A most preferable embodiment of such promoter gene
fragment for use in an exogenous gene expression in the
present invention is a gene fragment comprising a sequence of
from nucleotide 61 to nucleotide 557 in SEQ ID NO:1 of the
Sequence Listing. Since there are various subtypes of Marek's
disease virus, a mutation might possibly occur within a
portion of the gB promoter gene. For a sequence of gB
promoter gene to be used in the present invention, in case of
Marek's disease virus, any gB promoter sequence which is
highly homologous to the above sequence in SEQ ID NO:1 may be
used without any limitation for expression of an exogenous
gene.
CA 02196416 1997-01-30
-- .12 --
In addition to Marek's disease virus type 1, other
herpes viruses also have:' t.ruct:uz al. proteins with a highly
homologous amino acid Sequence o that of gB protein, and
thus, promoter sequences which control expression of these
proteins may also be used for_' construction of the recombinant
virus of the present invent-Jon.
An exogenous gene controlled by such gB promoters
for incorporation into the genomee of Marek's disease virus
includes various genes encoding proteins of a possible vaccine
antigen for various chicken diseases including viral diseases,
bacterial diseases, parasit:Ic diseeases, and the like. For
example, for preparing a polyvalent vaccine for use in
chickens, an exogenous gene to be incorporated includes a gene
encoding Newcastle disease virus (NDV) antigen (e.g. genes
encoding NDV-F protein or HN protein), a gene encoding a
glycoprotein of avian infectious laryngotracheitis (ILTV), a
gene encoding a viral structural protein of infectious bursal
disease virus (IBDV), e.g. genes encoding VP2 or a whole of
VP243, a gene encoding a spike protein of infectious bronchi-
tis virus (IBV), a gene encoding HA protein of Heamophilus
paragallinarum, a causative agent of infectious coryza, and
the like. As an antigen to be used for prevention of viral
diseases, since, in the case of inf lucnza virus, a nuclear protein
(NP) has been shown to be a key antigen effective for
prevention irrespective of serotype, a nuclear protein gene
in other viruses is possibly a critical antigen gene for
protection.
A
CA 02196416 1997-01-30
13
For expression of exogenous genes as mentioned
above, an expression cassette is constructed using the gB
invention and the cassette
promoter gene of the present cassette is
incorporated into MDV to prepare a pclyv dent:. vaccine with a
single virus (recombinant MSV) since MDV itself functions as
a vaccine against Marek' s disease virus. As desired, a
vaccine of more than 2 valencies can also be prepared, and a
polyvalent vaccine of more than 3 va_Lencies comprising only
one kind of a recombi nann virus can also be pr :pared by
incorporating a plurality of different foxe.:i_gn gene expression
cassettes into a single virus. Such a vaccine can easily be
prepared by utilizing the known prior art techniques.
The recombinant virus of the present invention may
be inoculated into chickens of any age. It should be noted
that the most characteristic feature of the recombinant virus
of the present invention in; that it can effectively be
inoculated into chickens having maters al antibodies, for
example, just after hatching. Furthermore, it is also
possible to inoculate at the stage of developing eggs, most
suitably at 17 to 18 day old embryos.
In addition to expression of the above-mentioned
vaccine antigens, the recombinant virus of the present
invention is also useful as a viral vector for expression of
physiologically active proteins other than the vaccine
antigens in inoculated animals. That:: is, since the recombi-
nant herpes virus of the present invention is not a transient
expression system but, when administered to animals, enables
A
CA 02196416 1997-01-30
14 -,.
persistent infection while escaping from the immune system
within the animal body, it is expected to be quite efficacious
as a drug delivery system (DDS) for effectively producing an
exogenous gene product within the living body.
The present invention is illustrated in more detail
by means of the following Preparation and Examples.
[Preparation]
(1) Viral strain
Marek's disease virus type 1 CV1988 strain was used
for cloning of gB promoter gene region and construction of a
recombinant virus.
(2) Preparation of viral DNA
After inoculation of the virus into chicken embryo
fibroblasts (CEFs), the infected cells were harvested when
cytopathic effect (CPE) was intensely exhibited. The infected
cells were suspended in l%-SDS solution (0.1% Tris-HC1, pH
7.4, 1 mM EDTA, 1% SarcocinateTM; manufactured by Wako Junyaku
Kogyo K. K. ) containing 0.1% Proteinase KTM(Boehringer Mannheim)
and the suspension was left to stand at 37 C overnight. Then,
the phenol treatment, and the ethanol precipitation were
conducted to recover DNAs, which were dissolved in a suitable
amount of TE buffer (10 mM Tris-HC1, pH 8.0, 1 mM EDTA) to
give a solution of viral DNAs.
(3) Cloning of viral DNA fragments
The thus prepared viral DNAs (5 g) were digested
with a restriction enzyme and fragments were separated by
electrophoresis on 0.8% agarose gel. The DNA fragments were
CA 02196416 1997-01-30
15 ..-
eluted from the gel by the electroelutton method and recovered
by the phenol treatment and the ethanol precipitation. The
obtained fragments were inserted into a suitable plasmid
vector (e.g. pUC119; Takarashuzo) with a ligation kit
(Takarashuzo) and competent c e:1..1 , ( n . cg . JM109) were trans-
formed with the vector to give t:ransformant E.coli. Then, the
transformant cells were grown on a circle grow medium (SIO101,
INC. ) containing 1.00 pg/m.l ampicilli.ri and thereafter the
plasmids were collected from the cells by the alkaline method.
(4 Determination of rrucl.eotic e sE. uencea
After cloning of the genie fragments into the
multiple cloning site of pUC119, the plasmids were transduced
into competent cells such as JM109. After the obtained
transformants were grown an LB medium overnight, 30 pl of the
transformants were infected with 60 pi of M13 phage (109
PFU/ml or more) and further grown by shaking the culture over-
night. After removing the cells by centrifugation, the phages
were collected from the supernatant. and a single-stranded DNA
(ssDNA) containing a nucleotide sequence of a desired gene
fragment was prepared by a known procedure. A. nucleotide
sequence of the obtained ssDNA was determined with
SEQUENASE Ver. 2.0 (Toyobo) in accordance with the protocol
attached thereto.
(5) PCR
The viral DNA (0 , ;.rg) was dissolved in 1 x Vent
buffer (10 mM KC1, 20 mM Tris-HC1, pH 8.8, 10 mm (NH4)2SO4, 2
A
2196416
16 -
mM MgSO4) containing 100 }ig/ml BSA and thereto were added 0.5
mM dNTP, each 100 pmmol of upstream and downstream primers and
1 pl Vent DNA polymerase (New England BioLabs). The reaction
was conducted for 35 cycles, each cycle consisting of 95 C for
1 minute, 55 C for 1 minute and 72 C for 1 minute.
(6) Fluorescent antibody (FA) method
CEF 106 cells/well were seeded to a 6-well plate
containing one cover glass (MATSUNAMI No.1 18x18) and cultured
on Eagle medium with 5% FBS at 37 C for 5 hours. After
washing twice with a serum free Eagle medium, 1 ml of a serum
free Eagle medium containing lipofectin 10 pg and the
insertion plasmid 30 pg was added and the cells were cultured
at 37 C for 16 hours. After addition of 1 ml Eagle medium
with 10% FBS and culture for 2 days, the cover glass was
removed and the cells were fixed with acetone at room
temperature for 20 minutes and then stored at -80 C. F
protein expression in the recombinant viruses was confirmed
by reaction with anti-NDV-F monoclonal antibody #313 [Y. Umino
et al., J. Gen. Virol. 71, p1199 (1990)] diluted 20-fold with
PBS(-) at 40C overnight and then by reaction with FITC-labeled
anti-mouse IgG diluted 20-fold with PBS(-) at 37 C for 2
hours, followed by washing and observation with a fluorescent
microscope.
(7) Preparation of recombinant virus
After primary culture CEFs, cultured at 37 C
overnight, were harvested and washed with an EDTA-trypsin
CA 02196416 1997-01-30
17
solution, they were suspended in Eagle-MEM (E-MEM: Nissui)
supplemented with 5% bovine serum (BS) at a cell concentration
of 2 x 105 cells/ml. A tissue culture flask manufactured by
Falcon (No. 3028) was charged with 40 ml. of the suspension and
thereto was seeded about 8 x 10 ' CEF cells infected with
Marek' s disease viruses, followed by culture at 37'C for 4
hours. Then, the cells were again harvested with a EDTA-
trypsin solution and washed twice with PBS(-), of which 5 x
106 cells were transferred to a cuvette of Gene PulserTM
manufactured by Bio-Rad (Catalogue No. 165-2075) and thereto
was added the insertion plasmids. Pulse was then applied in
accordance with the attached protocol to introduce the
insertion plasmids into the viral infected cells. Then, the
cells were suspended in E-MEM (Nissui) 15 ml supplemented with
5% BS, transferred to a laboratory dish of 10 cm diameter
(manufactured by Falcon; No.3003) and cultured at 37 C. The
next day, the culture medium was removed together with those
cells not being taken, and primary culture CEFs (second CEFs),
which were separately cultured the previous day and suspended
in E-MEM (Nissui) 15 ml supplemented with 5% BS at 5 x 105
cells/ml, were added and culture was continued at 37 C for 4
to 7 days.
After washing the laboratory dish where plaques
appeared with E-MEM medium, an isotonic solution containing
the monoclonal antibody #313 was added thereto and the
reaction was conducted at room temperature for 1 hour. After
44
CA 02196416 1997-01-30
- 18 -
washing, peroxidase--labeled mouse antibody (Bio-RadTM Code No.
172-1011) diluted 200-fold with an isotonic solution was added
thereto and the reaction was further conducted at room
temperature for 1 hour. After washing, thereto was added 0.1
M Tris buffer conta:in,..ng 5 mg o E: 3, 3-diaminobenzidine
tetrahydrochloride (DAD; Wako Junyaku Kogyo K.K., Code No.
343-00901) and 1 . 6 mg of hydrogen peroxide (Mitsubishi Gasu
Kagaku K.K., containing 31% H2O2) per 10 ml and the reaction
was carried out at room t.emperat:.ure for 10 to 60 minutes to
stain the plaques of the recombinant virus. The plaques
stained brown were enclosed with a penicillin cup and only the
area within the cup was digested with a trypsin solution
containing 0.1% EDTA to harvest cells infected with the
recombinant virus, which were cultured with fresh CEFs for
purification of the recombinant virus. After confirming that
100% of the viral plaques expressed F protein, ultrasonication
was conducted twice to render the virus being cell-free in
accordance with the procedures described in Japanese patent
application No. 4-205933 (Japanese patent publication No. 6-
22757) to complete purification of the recombinant virus.
(8) Southern hybridization
Using DIG-DNA Labeling Kit (Catalogue No. 150350)
manufactured by Boehringer Mannheim, probes were prepared and
hybridization was conducted in accordance with the attached
protocol.
A suitable amount of the recombinant virus DNA
obtained above was electrophoresed on an agar gel, and after
44
CA 02196416 1997-01-30
19 --
electrophoresis, it was transferred to HybondTM N+ (Amersham
Japan, Catalogue No. RPN.,303B) . Hybridization was carried out
in accordance with the protocol. Then, using DIG-DNA
Detection Kit (Catalogue No. 150350) manufactured by
Boehringer Mannheim, DNA of interest was detected in accor-
dance with the attached protocol.
(9) Immunization Test
Babcock chickens of 1 day old were inoculated
subcutaneously with 104 PFU/chicken of the recombinant virus.
Each group of chickens was bled periodically since 4 weeks
after inoculation and a change of a titer of anti-F protein
antibody induced by the recombinant virus was measured by
ELISA. ELISA for measuring antibodies was employed wherein
cells producing persistently F protein (mouse myeloma cells
P3-X63-AG8.653 transformed with NDV-F gene under control of
J3-actin gene promoter) immobilized on a 96-well plate for
tissue culture was used as an antigen as disclosed in detail
in Japanese patent application No. 5-96727 (Japanese patent
publication No. 6-289028).
On the other hand, in order to assess protective
effects against infection with Newcastle disease virus, a half
number of each group was challenged intramuscularly with a
lethal dose of 104 virulent NDV Sato strain at 6 weeks old and
was observed for 2 weeks. As to protective effects against
infection with Marek's disease virus type 1, intraperitoneal
challenge with 500 PFU/chicken of very virulent MDV (vvMDV)
44
CA 02196416 2008-09-19
- 20 -
RBIB (infected spleen cells) was made at 1 week old and
chickens were observed until 10 weeks old. All surviving
chickens were subjected to necropsy to check the presence of
tumoral lesion.
(10) Recovery of virus from the chicken body
After bleeding with a 1 ml heparin-sucked syringe,
PBS(-) was added to make 4 ml, which was gently overlaid to
Ficoll-Paque TM (Pharmacia) 3 ml in conical tube (Falcon,
Catalogue No. 2099) and was centrifuged at 1500 rpm for 5
minutes (KUBOTATM KN-30F). A middle layer comprising lympho-
cytes and monocytes (Buffy coat) was removed and, after being
suspended in PBS(-) containing 0.1% EDTA, was again centri-
fuged at 1000 rpm for 5 minutes to collect lymphocytes and
monocytes, which were inoculated to CEFs cultured for 4 hours
(second CEFs) and CEFs were cultured and observed for 10 days.
For those CEFs which exhibited no CPE of MDV, they were
subcultured to the 3rd generation and then assessed.
[EXAMPLE]
Using by way of example a vector wherein a Marek's
disease virus is used as a herpes virus, cloning of gB
promoter region and construction of recombinant virus are
illustrated hereinbelow for construction of recombinant live
vaccine for chicken.
Example 1: Determination of nucleotide sequence upstream of
qB gene
BamHI-I3 fragment comprising a nucleotide sequence
of gB gene as described by Ross et al. [J. Gen. Virol. 70,
2196416
- 21 -
p1789-1804 (1989)] was digested with restriction enzymes EcoRV
and SspI and the obtained fragment of about 1.2 Kbp was
subcloned into pUC119. As described in Preparation, a
nucleotide sequence was determined for a region further
upstream of gB gene using the plasmid. A nucleotide sequence
of about 300 bp to upstream direction was first determined and
then determination of a nucleotide sequence was made to
downstream direction up to the SspI site so that a total of
557 bp nucleotide sequence was determined. The result is
shown as SEQ ID NO: 1. A sequence from the nucleotide 558 to
the translation initiation codon ATG (nucleotide 624) in SEQ
ID NO: 2 is at the 3' site of the above 557 bp sequence and
has been reported by Ross et al. (ibidem). The primer which
the present inventors used for determination of nucleotide
sequence corresponds to the nucleotides 275 to 291 in SEQ ID
NO: 1.
Example 2: Cloning of gB gene promoter region by PCR
Primers were designed based on the nucleotide
sequence obtained in Example 1 (cf. SEQ ID NO: 1) for an
upstream primer or on the sequence reported by Ross et al. [J.
Gen. Virol. 70, p1789-1804 (1989)] for a downstream primer.
That is, an upstream primer was designed between the
nucleotides 61 and 82 in SEQ ID NO: 1 and a downstream primer
between the nucleotides 566 and 586. Each sequence of the
primers are shown below.
Upstream
5'-GGAATTCCGTGTTGAAAATGTAGGGCTGCT-3'
J
2196416
- 22 -
Downstream
5'-GGAATTCCTGTGAGATAAAATGCAGGGAC-3'
PCR conditions were as follows: i.e. the viral DNA
0.1 g was dissolved in 1 x Vent buffer (10 mM KC1, 20 mm
Tris-HC1, pH 8.8, 10 mM (NH4) 2SO4, 2 MM MgSO4) containing 100
gg/ml BSA and to the solution were then added 0.5 mM dNTP,
each 100 pmmol of the upstream and downstream primers and 1
l Vent DNA polymerase (New England Biolabs). The reaction
was conducted for 35 cycles, each cycle consisting of 95 C for
1 minute, 55 C for 1 minute and 72 C for 1 minute. As a
result, a DNA fragment of about 0.5 Kbp was successfully
amplified. This DNA fragment was digested with EcoRI and SspI
to give a DNA fragment of about 0.5 Kbp (hereinafter referred
to as "fragment P", a nucleotide sequence of which corresponds
to the nucleotides 61 to 557 in SEQ ID NO: 1) and with EcoRI
and NdeI to give a DNA fragment of 230 bp (hereinafter
referred to as "fragment N", a nucleotide sequence of which
corresponds to the nucleotides 359 to 586 in SEQ ID NO: 2) as
a gB gene promoter region (cf. Figs. 1 and 2).
Example 3: Construction of insertion vector plasmid for
expression of NDV-F protein via q-B promoter
After digesting insertion vector plasmid pKA4BLF
(described in Japanese patent application No. 4-205933
(Japanese patent publication No. 6-22757)), which expresses
NDV-F protein via SV40 late promoter, with restriction enzymes
Hindlil and XbaI, a DNA fragment of about 7.9 Kbp deprived of
SV40 late promoter sequence was recovered by 0.8% agar gel
2196416
23 -
electrophoresis. After this fragment was blunt-ended with
Blunt End Ligation Kit (TaKaRa), gB gene promoter fragment P
or N was cloned. Among the obtained plasmids, a plasmid
comprising gB promoter fragment P in a right direction, i.e.
in a direction enabling NDV-F protein expression, was referred
to as "pKA4BPF" and a plasmid comprising fragment N in a right
direction was referred to as "pKA4BNF" (Fig. 3).
Example 4: Determination of NDV-F protein expression by
fluorescent antibody method
FA was conducted as described in Preparation, and
as a result, both pKA4BPF and pKA4BNF were proved to express
NDV-F protein in CEFs. No distinction in fluorescent
intensity was observed between cells where each plasmid was
introduced and thus it was estimated that promoter activities
of both fragments P and N in CEFs were substantially the same.
Example 5: Preparation of recombinant viruses US10BPF and
US1OBNF
After each of insertion plasmids pKA4BPF and pKA4BNF
constructed in Example 3 was digested with restriction enzyme
Scal to linearize, these plasmids were introduced into CV1988
strain-infected cells as described in Preparation of recombi-
nant virus. The thus obtained recombinant viruses were
referred to as "USIOBPF" and "USlOBNF", respectively. Plaques
of the recombinant viruses were stained with anti-F protein
monoclonal antibody-DAB (Japanese Patent application No. 4-
205933 (Japanese Patent Publication No. 6-22757)). As a
result, no significant difference was observed in an expressed
CA 02196416 1997-01-30
amount of F protein by both recombina:nt. viruses and thus it
was estimated that the promoter activities of fragments P and
N in culture cel [.,s were the .,anie.
In order to confirm the insertion position of the
expression cassette in both recombinant viruses US10BPF and
USIOBNF, DNAs extracted from infected CEFs were digested with
restriction enzymes and then Southern hybridization was
conducted. With the use of any of gB promoter fragment P or
A4 used as a probe, only those bands as expected were detected
to confirm that insertion of the expression cassette was
carried out by homologous recombination and that purification
of the recombinant viruses surely occurred (Figs. 4 and 5).
Example 6: Immunization test
In order to prove vaccine effects of the prepared
US10BPF and US1OBNF against Newcastle disease (ND), chickens
of 1 day old were inoculated with these recombinant viruses
and challenge test was conducted 6 weeks later. The results
are shown in Table 1. U310BL1!`' used. here-in as one of the controls
is a recombinant virus wherein expression of F protein is
under control of SV40 late promoter which is prepared with
insertion plasmid pKA4BF, a construction of which is disclosed
in Japanese Patent application No, 4-205933 (Japanese Patent
Publication No. 6-22757). This recombinant vi.:-us exhibits
strong vaccine effects against NDV challenge in SPF chickens
but ND protective effects are decreased in chickens having a
maternal antibody as shown in Table 1.. As shown in Table 1,
control chickens and SPF chickens with no inoculation
It
2196416
- 25 -
exhibited 0% of protection rate whereas inoculation with
US10BPF protected all individuals, even chickens having a
maternal antibody, and thus those recombinant viruses where
F protein is expressed under control of gB gene promoter
exhibited excellent vaccine effects. However, the recombinant
virus USIOBNF, comprising gB-N promoter, one of gB promoters
with half length of gB-P promoter, exhibited no protective
effects. Although US1OBNF showed F protein expression in
culture cells at the same level as that of US10BPF, the
protective effects in vivo were much different between US10BPF
and US1OBNF, which suggested that the use of gB-P region as
a promoter is critical for expression of an exogenous gene in
recombinant viruses to be administered into the living body.
As to vaccine effects against Marek's disease (MD),
as is clear from Table 2, the recombinant virus US10BPF of the
present invention was proved to exhibit 90% protection rate
against very virulent Marek's disease virus type 1, the
protective rate being equivalent to or more than those of the
parent strain (non-recombinant), 89%, or commercially
available MDV1 vaccine, 84%.
As mentioned above, the recombinant virus US10BPF
of the present invention was proved to exhibit strong
protection effects against both Newcastle disease (ND) and
Marek's disease (MD) viruses and thus to be useful as a
polyvalent vaccine.
CA 02196416 1997-01-30
- 26
Table 1
Protected chickens No,/
Inoculated virus Promoter Challenged chickens No.
(p.) c tecti.on ratio
US10BLF SV40 late 14/20 (70%)
US10BPF gB-P 20/20 (100%)
US1OBNF gB-N 0/20 (0%)
No inoculation - 0/20 (0%)
Table 2
Virus Inoculated Tested chick- MD onset MD Protection
amount (PFU) ens (No.. ___ Nc:L. _,____ ratio (%)
US10BPF 10000 20 2 90%
1000 20 6 70%
*1 10000 19 2 89%
1000 20 9 55%
*2 1 dose 19 3 84%
*3 (-) 20 i9 5%
*1: Non-recombinant virus (parent strain)
*2: Commercially available MDV1 vaccine
*3: No immunization
A change of anti-F antibody titer in chicken serum
as measured by ELISA is shown in Fig. 6. An antibody titer in
no inoculation group is of maternal antibodies and was observed
to be decreased with the passage of time. In the case of
US10BLF, it was only after maternal. antibodies have decreased
to some extent, i . e . at 5th to 6th weeek, that anti -F protein
antibody titer started to increase. On the other hand, in the
case of chickens inoculated with USIOBPF, antibody titer
increased as soon as, at the 4th week, and at the 6th week when
challenge was given, was much higher than that of US10BLF.
In this connection, US1OBNF showed somewhat increase in an
antibody titer at 5th to 6th week: but not to such an
A
CA 02196416 1997-01-30
.... 2 7 --
extent that could protect from Newcastle disease virus
challenge, supporting the results of challenge test.
A change of an anti-F antibody titer was observed
over a year for chickens inoculated with US10BPF and the
results are shown in Fig. 7. An anti-F antibody titer
throughout the year exceeded the anti-F antibody titer for the
group inoculated with US10BLF, i.e. 0..65 (Fig. 6), which was
obtained when it showed 70% protection ratio (Table 1) in
challenge test with Newcastle disease virus, indicating that
in most of the individuals the vaccine effects of the
recombinant virus continue to be effective for at least one
year.
Virus was recovered at the 7th week after inoculation
and the results are shown in Table 3. US10BLF showed 0/5(+),
i.e. no viral recovery, whereas US10BPF was 5/'5(4), i.e. high
viremia, suggesting that IJSIOBPF exhibits excellent propaga-
tion in vivo. Furthermore, all. the plaques of recovered
recombinant virus were proved to express F protein, confirming
that the recombinant virus of the present invention is
genetically stable even in vivo and infects persistently.
This demonstrates that the virus vector system of the present
invention is not merely a transient expression system but
persistently infects even in the presence of a maternal
antibody and thus can be quite useful as a drug delivery
system (DDS) for efficiently producing an exogenous gene
product within the living body. Accordingly, the system of
the present invention is not only a vector for administration
A
2196416
- 28 -
of vaccine but also DDS being quite useful for delivery of
such substances as required to be supplied for a long period
of time within the living body such as hormones or cytokines.
Table 3
Inoculated Promoter Chicken Viral recovery
virus No. Recovery Ratio of recom-
binant virus
US10BLF SV40 late 61 -
62 -
63 -
64 -
65 -
US10BPF gB-P 51 + 69/69
52 + 47/47
53 + 22/22
54 + 9/9
55 + 48/48
CA 02196416 1997-05-01
_'29..
SEQUENCE LISTING
APPLICANT: Juridical Foundation The Chemo-Sero-
Th.erapeutic Research Institute
TITLE OF INVENTION: Recombinant Herpes Virus with gB Gene
Promoter
NUMBER OF SEQUENCES: 2
CORRESPONDENCE ADDRESS: Kirby Eades Gale Baker.
P..O. Box 3432, Station D
Ot:.tawa, Ontario
Canada K.1P 6N9
COMPUTER-READABLE FORM
COMPUTER: IBM
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect
CURRENT APPLICATION DATA
APPLICATION NUMBER: CA 2,196,416
FILING DATE: May 28, 1996
CLASSIFICATION:
PRIOR APPLICATION DATA
APPLICATION NUMBER: JP 160106/1995
FILING DATE: June 2, 1995
CLASSIFICATION:
PATENT AGENT INFORMATION
NAME: Kimberley Lachaine
REFERENCE NUMBER: 39611-NP
SEQ ID NO: 1
SEQUENCE LENGTH: 557
SEQUENCE TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
ORIGINAL SOURCE:
ORGANISM: Marek's disease virus type 1
CA 02196416 1997-05-01
-30-
SEQUENCE DESCRIPTION:
GATGTTTAGT CACGATAGAC ATCGGTTCGC CCCAGCCGTC. GAATACAGCA TTATATTTTA 60
GTGTTGAAAA TGTAGGGCTG CTTCCTCACT TAAAGGAGGA AATGGCTC"GA TTC.ATGTTTC:: 120
ATAGCAGTAG AAAAACAGAT TGGACCGTCA GTAAGTTTAG AGGGTTTTAT GACTTTAGCA 180
CTATAGATAA TGTACTGCGG CCCATCGCAT GGC'TTGGAAA TAT'ATCAAAG AACTGATTTT 240
TGCAACAGCT TTATTTTCTT C'TGTATTTAA ATG'TGGCGAA TTGCACATCT GTCGTGCCGA 300
CAGTTTGCAG ATCAACAGCA ATGGAGACTA TGTATGGAAA AATGGAATAT ATATAACATA 360
TGAAACCGAA TATCCACTTA TAATGATTCT GGGGTCAGAA TCAAGCACTT CAGAAACGCA 420
AAATATGACT GCAATTATTG ATACAGATGT TTTTTCGT'TG CTTTATTC"TA. 'TTTGCAGTA. 480
TATGGCCCCC GTTACGGCAG ATCAGGTGCG AGTAGAACAG AT'TACCAACA GCCACGCCCC'' 540
CATCTGACCC GTCCAAT 557
SEQ ID NO: 2
SEQUENCE LENGTH: 624
SEQUENCE TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
ORIGINAL SOURCE:
ORGANISM: Marek`s disease virus type 1
SEQUENCE DESCRIPTION:
GATGTTTAGT CACGATAGAC ATCGGTTCGC CCCAGCCGTC GAATACAGCA TTATATTTTA 60
GTGTTGAAAA TGTAGGGCTG CTTCCTCACT TAAAGGAGGA AATGGCTCGA TTCATGTTTC' 120
ATAGCAGTAG AAAAACAGAT TGGA('.:CGTCA GTAAGTTTAG AGGG'TTTTAT GACTTTAGCA 180
CTATAGATAA TGTACTGCGG CCCATCGCAT GGCTTGGAAA TATATCAAAG AACTGA.T'TTT 240
TGCAACAGCT TTATTTTCTT CTGTATTTAA ATGT'GGCGAA TTGCACATCT GTCGTGCCGA 300
CAGTTTGCAG ATCAACAGCA ATGGAGACTA TGTATGGAAA AATGGAATAT ATATAACATA 360
TGAAACCGAA TATCCACTTA TAATGATTCT GGGGTCAGAA TCAAG:GCACTT CAGAAACGCA 420
AAATATGACT GCAATTATTG ATACAGATGT TTTTTCGTTG CTTTATTCTA TTTTGCAGTA 480
TATGGCCCCC GTTACGGCAG ATCAGGTGCG AGTAGAACAG AT'TACCAACA GCCACGCCCC 540
CATCTGACCC GTCCAATATT CTTGTGT'CCC TGCATTTTAT CTCACACAAT TTATGAACAG' 600
CATCATTAAG ATCATCTCAC TATG 624
